港股异动|昊海生物科技涨4.36%A股发行获科创板股票上市委员会审核通过
格隆汇7月16日丨昊海生物科技(06826.HK)涨4.36%,报47.9港元,成交347.2万港元,总市值76.66亿港元。7月15日,科创板上市委召开第15次审议会议,审议通过了上海昊海生物科技股份有限公司的科创板首发申请。昊海生科的上市申请于4月18日获得受理,到过会用时接近三个月。昊海生科主要应用生物医用材料技术和基因工程技术进行医疗器械和药品研发、生产和销售,主要产品分为眼科、整形美容与创面护理、骨科、防粘连及止血四大板块,包括药品和医疗器械产品。昊海生科曾经两度冲击创业板上市,但均未成功。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.